How Long Will You Stay on — Osimertinib?

You stop taking osimertinib and move to regular follow-up — typically CT scans every six to twelve months, as your oncologist advises, to check that the cancer has not returned. There is no evidence that continuing beyond three years adds benefit, and the three-year course is what the trial data supports. Stopping on schedule is not a risk; it is the plan working as intended. If you feel anxious about stopping, that is worth raising with your team before the end date.

Your oncologist will arrange CT scans at regular intervals — typically every two to three months at first, then less frequently if things are stable. If scans show the tumour has grown by a measurable amount, or if new sites of disease appear, that is progression. A single ambiguous scan usually prompts a repeat rather than an immediate decision to stop, so you will not be taken off the drug based on one inconclusive image. New symptoms between scans — new pain, breathlessness — are also worth reporting rather than waiting.

A planned pause is sometimes considered for severe side effects, and NCCN guidance allows for dose interruption in certain situations. The decision depends on the side effect, its severity, and whether you are taking osimertinib after surgery or for advanced disease — the implications of a gap are different in each setting. Do not stop without telling your team first, because some side effects need active treatment before restarting, and an unplanned gap matters for both your safety and your disease control.

Consistency matters. Osimertinib is taken once daily, and the steady level of drug in your system is part of how it suppresses the cancer. Occasional missed doses are unlikely to have a large effect, but frequent missed doses mean the cancer is not being controlled as reliably. If you are struggling to take it consistently — because of nausea, cost, or something else — tell your team so they can help. Missed doses you do not mention are the situation to avoid, because you lose both the treatment effect and the chance to fix the underlying problem.

Your oncologist will discuss what comes next, which depends on how the cancer has progressed and what other treatments you have already had. Further molecular testing on a new biopsy or a liquid biopsy is often done at progression to look for new mutations that can guide the next choice. Options may include chemotherapy, another targeted agent if a new actionable mutation is found, or a clinical trial. Your oncologist will go through the realistic options for your specific situation at that point.

Three years is the duration established by the ADAURA trial and currently recommended by NCCN and ASCO for adjuvant osimertinib. Whether a longer course would add further benefit is not yet known — studies to answer that are ongoing. Until those results are available, three years remains the standard. If guidance changes, your oncologist will tell you; you do not need to track this yourself. Asking your team at your annual review whether anything has changed is entirely reasonable.